For the 67 million Americans enrolled in Medicare, 2026 marks a turning point in access to GLP-1 weight loss medications. After years of explicit exclusion under Part D's anti-obesity drug carve-out, the Centers for Medicare and Medicaid Services (CMS) announced the Bridge Program, which will begin covering FDA-approved GLP-1 medications for weight loss starting July 1, 2026. This guide covers everything seniors need to know about eligibility, costs, enrollment, and what comes next.
What Is the Bridge Program?
The Medicare GLP-1 Bridge Program is a temporary coverage initiative running from July 1 through December 31, 2026. It was created in response to the Inflation Reduction Act's expanded definition of covered Part D drugs, which now includes FDA-approved anti-obesity medications for beneficiaries who meet specific clinical criteria. CMS has structured it as a bridge because permanent formulary integration requires a full plan year cycle, which will begin with the 2027 plan year.
Under the Bridge Program, Medicare Part D plans will cover three GLP-1 medications: Wegovy (semaglutide injection), Zepbound (tirzepatide injection), and Foundayo (orforglipron oral tablet). The beneficiary copay is capped at $50 per month, regardless of which medication is prescribed. This cap applies after any applicable deductible has been met, though CMS has encouraged plans to waive the deductible for Bridge Program drugs.
Eligibility Requirements
To qualify for GLP-1 coverage under the Bridge Program, Medicare beneficiaries must meet the following criteria:
- Enrolled in a Medicare Part D prescription drug plan (standalone PDP or Medicare Advantage with Part D)
- BMI of 30 or greater, or BMI of 27 or greater with at least one weight-related comorbidity (type 2 diabetes, hypertension, dyslipidemia, obstructive sleep apnea, or cardiovascular disease)
- Prior authorization from the prescribing physician, including documentation of BMI and relevant comorbidities
- Prescription from a licensed healthcare provider (MD, DO, NP, or PA)
Importantly, a prior trial of lifestyle modification (diet and exercise) is not required for Bridge Program eligibility, though some Part D plans may include this as a step therapy requirement. CMS has discouraged but not prohibited step therapy for Bridge Program drugs.
What Will It Cost?
The $50 monthly copay cap is the headline number, but the full cost picture is more nuanced. Here is how it breaks down:
- Monthly copay: $50 maximum (some plans may offer lower copays)
- Annual deductible: Standard Part D deductible is $590 in 2026; some plans may waive it for Bridge Program drugs
- Annual out-of-pocket cap: $2,000 under the IRA's redesigned Part D benefit (applies to all Part D spending, not just GLP-1 drugs)
- Manufacturer savings cards: Cannot be applied to Part D prescriptions; these are only valid for commercial insurance or self-pay
For detailed cost comparisons across providers, GLP-1 Watchdog tracks real-time GLP-1 pricing.
The CMS Balance Model
One of the biggest concerns about the Bridge Program was what would happen when it expired on December 31, 2026. CMS addressed this with the Balance Model, a framework that ensures Part D plans incorporate GLP-1 coverage into their 2027 formularies. Under the Balance Model, CMS will subsidize a portion of the catastrophic coverage costs for GLP-1 drugs, reducing the financial risk to Part D plan sponsors and making it economically viable for them to continue coverage beyond the Bridge Program.
This is critical because without the Balance Model, many Part D plans would have dropped GLP-1 coverage after the Bridge Program ended, citing unsustainable costs. The Balance Model does not guarantee identical $50 copays in 2027, but it ensures that coverage will continue and that beneficiary costs will remain within the $2,000 annual out-of-pocket cap.
How to Prepare Now
If you are a Medicare beneficiary interested in GLP-1 coverage, here is what you should do before July 1:
- Schedule a visit with your doctor. Discuss whether a GLP-1 medication is appropriate for your health situation. Your provider will need to complete the prior authorization paperwork.
- Check your Part D plan. Contact your plan to confirm they will participate in the Bridge Program. While CMS expects broad participation, not every plan may be ready on day one.
- Get your BMI documented. Your medical record should include a recent BMI measurement and documentation of any weight-related comorbidities.
- Review the $2,000 OOP cap. If you take other expensive medications, factor GLP-1 costs into your total Part D spending for the year.
What About Medicare Advantage?
Medicare Advantage (MA) plans that include Part D coverage (MA-PD plans) are also required to participate in the Bridge Program. However, MA plans have additional flexibility in how they structure prior authorization and step therapy requirements. Some MA plans may require referral to a network endocrinologist or obesity medicine specialist before approving a GLP-1 prescription. Check with your specific plan for details.
The Bigger Picture
The inclusion of GLP-1 medications in Medicare coverage is arguably the most significant expansion of Part D since the program launched in 2006. CMS estimates that 3.4 million Medicare beneficiaries meet the clinical criteria for GLP-1 treatment. Even if only a fraction of eligible beneficiaries enroll in the first six months, the Bridge Program will dramatically expand access to medications that have been shown to reduce cardiovascular events, improve glycemic control, and enhance quality of life in addition to promoting weight loss.
The long-term fiscal impact remains debated. Proponents argue that the cost of GLP-1 drugs will be offset by reductions in hospitalizations, surgeries, and chronic disease management costs. Critics worry about the sheer volume of potential beneficiaries overwhelming the Part D budget. The truth will likely fall somewhere in between, and the 2027 Balance Model data will be the first real test of the program's sustainability.